4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
ACADIA Pharmaceuticals Inc. (ACAD) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 796 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, ACAD reported $1.1B in revenue and $391M in net income.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
Interactive charts & full statements → Open the ACAD valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $1.1B | $958M | $726M | $517M | — |
| Gross Profit | $982M | $876M | $685M | $507M | — |
| Operating Income (EBIT) | $105M | $84M | ($73M) | ($224M) | — |
| Net Income | $391M | $226M | ($61M) | ($216M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $268M | $284M | $279M | $265M | $244M |
| Gross Profit | $243M | $258M | $257M | $244M | $224M |
| Operating Income (EBIT) | ($5M) | $17M | $36M | $32M | $19M |
| Net Income | $4M | $274M | $72M | $27M | $19M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $1.6B | $1.2B | $749M | $588M | — |
| Total Liabilities | $337M | $455M | $317M | $187M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ACAD viewer.
About TickerBase · Data methodology & sources